ITHAX Acquisition Corp. III 3Q 2026: Net income $1.97M — 10-Q Summary

ITHAX Acquisition Corp. III reported a net income of $1.97M for the quarter, reversing a loss from the prior-year period, driven by trust-account interest income. The company has not yet commenced operations. It has until December 15, 2027, to complete a business combination. The trust account held $236.4M in cash and marketable securities as of September 30, 2026, according to the company.

Original reporting
Published Nov 13, 2026, 10:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 10:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ITHAX Acquisition Corp. III 3Q 2026: Net income $1.97M — 10-Q Summary — source image
Decision brief

The 30-second read

$ITHANeutralLow
01

Why it matters

The net income result is a positive data point but unlikely to drive significant price movement given the lack of operating revenue and the large trust balance.

02

Market read

Modest profit disclosure for a SPAC; limited trading relevance.

03

What to watch

Liquidity outside the trust is minimal and the deadline for a merger is late 2027, adding execution risk.

Relevance 4/10Novelty 4/10Timing: post‑10‑Q release

Background

Ithax Acquisition Corp. III (ticker ITHA) is a SPAC that has not yet completed a business combination. The filing reports its first quarterly profit.

Company-level read

Ticker impact

$ITHANeutralMedium confidence
Context

Quarterly 10‑Q shows net income of $1.97 M versus a loss a year ago, the first profit report for the SPAC.

Expected impact

potential modest upside as investors price in the turnaround to profit

Evidence & confidence

Profit is small relative to the $236 M trust balance; market reaction is likely muted.

Market effects

SPAC sector sees a rare profit signal, but no broader impact.

U.S. market only; no regional effect.

Limited to investors tracking SPACs.

Counterpoint

The profit may be a red herring; without a business combination the SPAC could still collapse.

Key entities

  • ITHAX Acquisition Corp. III

    SPAC awaiting business combination, ticker ITHA.

Related articles

$SBCHigh

Why SBC Medical Stock Skyrocketed on Friday

SBC Medical Group (NASDAQ:SBC) shares rose 37% after reporting Q3 revenue of $59M, up 35% YoY, and announcing an AI partnership with NeuroBrain Dynamics. The company added 36 clinics, increasing total locations to 293, and saw a 9% rise in patient visits. Operating income surged 66% to $26M, with a 45% operating margin.

$BTOMedAI 8/10

B2Gold Earnings Call Signals Lower Costs and Growth

B2Gold Corp. reported Q3 earnings with strong production, lower cost guidance, and positive free cash flow. The company produced 193,000 ounces of gold, reduced all-in sustaining cost guidance by over $100 per ounce, and generated $48 million in free cash flow. Revenue reached $836 million, supported by higher gold prices. The company also highlighted growth projects and shareholder returns.

$NMAXMed

Why Newsmax Stock Popped on Friday

Newsmax (NMAX) shares rose 31% after reporting Q3 revenue of $69M, up 52.5% YoY, and net income of $15.2M. The company cited strong audience engagement and growth in high-margin revenue streams. CEO Christopher Ruddy expects continued growth ahead of the presidential election.

$LUNRMed

What Is Driving Intuitive Machines Stock?

Intuitive Machines (LUNR) shares rose 7.0% on Nov 12, 2026, after reporting Q3 revenue of $269M, beating estimates. The company's loss of $0.10 per share met expectations, while gross margin improved to 26%. Free cash flow turned positive at $33M, a company record. Management raised full-year revenue guidance to $920M-$950M. The stock's performance contrasted with broader industry declines.

$RMIXMedAI 8/10

Suncrete (RMIX) Q3 2026 Earnings Call Transcript

Suncrete (RMIX) reported Q3 2026 revenue of $141M, up 45% QoQ and 163% YoY. Adjusted EBITDA rose 66% QoQ to $22.4M. The company lowered its full-year outlook due to residential construction weakness but remains confident in long-term demand. Acquisition integration is progressing, with North Texas showing margin improvement. Suncrete expects $200M-$250M revenue from 2026 acquisitions in 2027. The company has $206.5M in total liquidity.

$CLLSMed

Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene

Cellectis SA (CLLS) discussed its strategic shift to gene editing during its Q3 2026 earnings call. Management highlighted the selection of APOC3 over ANGPTL3 for triglyceride reduction, with plans to start Phase 1 dosing by end-2027. The company reported $149M in cash as of September 30, 2026, with a runway into H2 2028. Revenue decreased to $19.9M from $67.4M YoY, while R&D expenses increased to $108.8M from $69.1M, driven by the AstraZeneca collaboration.